Login to Your Account



Other News To Note


Friday, December 17, 2010
• Orexo AB, of Uppsala, Sweden, said partner Boehringer Ingelheim GmbH, of Ingelheim, Germany, selected a development candidate from the firms' 2005 collaboration focused on pain and inflammatory diseases. That selection triggered a €6.5 million (US8.6 million) milestone payment to Orexo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription